Bioworld Technology CO., Ltd.

RUNX1 (T270) Peptide

Cat No.: BS1717P

Background

AML1 (also known as Runx1, CBFA2, and PEBP2αB) is a member of the core binding factor (CBF) family of transcription factors. It is required for normal development of all hematopoietic lineages. AML1 forms a heterodimeric DNA binding complex with its partner protein CBFβ and regulates the expression of cellular genes by binding to promoter and enhancer elements. AML1 is commonly translocated in hematopoietic cancers: chromosomal translocations include t(8;21) AML1-ETO, t(12;21) TEL-AML, and t(8;21) AML-M2. Phosphorylation of AML1 on several potential serine and threonine sites, including Ser249, is thought to occur in an Erk-dependent manner.

Swiss-Prot

Q01196

Applications

Blocking

Specificity

This peptide can be used with studies using BS1717 RUNX1 (T270) pAb.

Purification & Purity

Synthetic peptide RUNX1 (T270). (Note: the amino acid sequence is proprietary). The purity is > 98%.

Product

1 mg/ml in DI water.

Storage & Stability

Store at 4℃ short term. Aliquot and store at -20℃ long term. Avoid freeze-thaw cycles.

Research Use

For research use only, not for use in diagnostic procedure.

Bioworld Technology, Inc.
1660 South Highway 100, Suite 500 St. Louis Park,MN 55416,USA. **Email: info@bioworlde.com**
Tel: 6123263284 **Fax: 6122933841**

Bioworld technology, co, Ltd.
No 9, weidi road Qixia District Nanjing, 210046, P, R.China. **Email: info@biogot.com**
Tel: +86-025-68037686 **Fax:+86-025-68035151**